Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NATRECOR

« Back to Dashboard

Natrecor is a drug marketed by Scios Llc and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

The generic ingredient in NATRECOR is nesiritide recombinant. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nesiritide recombinant profile page.

Summary for Tradename: NATRECOR

Suppliers: see list1

Pharmacology for Tradename: NATRECOR

Clinical Trials for: NATRECOR

Natrecor for Pulmonary Hypertension in Lung Transplants
Status: Completed Condition: Pulmonary Hypertension

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Status: Completed Condition: Congestive Heart Failure

Use of Nesiritide in the Management of Acute Diastolic Heart Failure
Status: Terminated Condition: Heart Failure; Cardiovascular Disease; Acute Heart Failure; Diastolic Heart Failure; Congestive Heart Failure; Heart Disease

Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Status: Withdrawn Condition: Heart Failure, Congestive; Dyspnea; Pulmonary Edema

Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery
Status: Terminated Condition: Heart Defects, Congenital

Natrecor in Pulmonary Hypertension
Status: Terminated Condition: Pulmonary Hypertension; Cancer; Lung Disease; Cardiothoracic Surgery

Nesiritide and Vo2 Max in Heart Failure Patients
Status: Completed Condition: Heart Failure

Nesiritide Use Following Cardiac Surgery in Infants
Status: Terminated Condition: Heart Defects, Congenital; Cardiopulmonary Bypass

Nesiritide and Renal Function After the Total Artificial Heart
Status: Terminated Condition: Congestive Heart Failure; Cardiorenal Syndrome

Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction
Status: Completed Condition: Acute Myocardial Infarction

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scios Llc
nesiritide recombinant
FOR SOLUTION;INTRAVENOUS020920Aug 10, 2001RXYes5,114,923<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology